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Residual ɣH2AX foci after ex vivo irradiation of patient samples with known tumour-type specific differences in radio-responsiveness   Apostolos Menegakis a,b,⇑, Chiara De Colle d, Ala Yaromina e, Joerg Hennenlotter f, Arnulf Stenzl f, Marcus Scharpf g, Falko Fend g, Susan Noell h, Marcos Tatagiba h, Sara Brucker i, Diethelm Wallwiener i, Simon Boeke a,b, Umberto Ricardi d, Michael Baumann c,j,k,l, Daniel Zips a,b  Department of Radiation Oncology, Medical Faculty and University Hospital, Eberhard Karls University Tübingen; b German Cancer Research Center (DKFZ), Heidelberg and German Consortium for Translational Cancer Research (DKTK) Partner Sites Tübingen; c German Cancer Research Center (DKFZ), Heidelberg and German Consortium for Translational Cancer Research (DKTK) Partner Sites Dresden, Germany; d Department of Oncology, Radiation Oncology, University of Turin, Italy; e Department of Radiation Oncology (Maastro), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands ; f Department of Urology; g Department of Pathology; h Department of Neurosurgery; i Department of and Research Institute for Women’s Health, Medical Faculty and University Hospital, Eberhard Karls University Tübingen; j Department of Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität; k OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden; and l Helmholtz-Zentrum Dresden – Rossendorf, Germany  Heterogeneity of tumour radiation response forms the biological basis of personalized radiation oncology. Towards this approach, robust and rapidly available biomarkers informing about the radiobiological characteristics of a given tumour are prerequisite to identify eligible patient subgroups for individualized intervention [1–11]. Among other radiobiological factors, intrinsic radiation sensitivity of tumour cells represents a major component attributing to treatment outcome [3,12–14]. Intrinsic cellular radiation sensitivity correlates with the number of residual unrepaired DNA double strand breaks (DSBs) [15–17]. Therefore, assessment of intrinsic radiation sensitivity through quantification of DNA DSBs has become increasingly utilized in translation cancer research [18–20]. Among other proteins involved in DNA damage response (DDR), the phosphorylated histone variant H2A, i.e. H2AX, has attracted particular attention. Upon irradiation or other exogenous stress, numerous molecules of H2AX are rapidly phosphorylated at the flanking sites of chromatin where DSBs have been induced forming the so-called cH2AX nuclear foci [21–31]. The fact that phosphorylation remains at the sites of DSBs until the end of repair processes before the foci are dephosphorylated [32–36] facilitates the study of foci disappearance along with the quantitative evaluation of residual DSBs [20,21,23,29,37–41]. In several studies both these endpoints have been correlated with cellular radiation sensitivity in vitro and in vivo either in tumour or normal tissue samples [20,21,23,28,29,31,37,39,41,42]. Taking together, the cH2AX assay is simple, sensitive and straightforward method to quantify DSBs in cells and tissues and therefore promising for translation into clinical trials. For clinical application, we have developed and pre-clinically validated a novel method using residual cH2AX foci in ex vivo irradiated tumour specimens [40,43–45]. In the present study we analyse data using the optimizedprotocol in 25 patient-derived surgical specimens (including 7 previously published [45]) covering a spectrum of 10 tumour types with 
known differences in radiation response, i.e. radiosensitive types such as seminomas and resistant types as chondrosarcomas. We hypothesized that the number of residual cH2AX foci corresponds to the expected tumour radiation sensitivity. In addition, in order to enhance clinical practicability for future studies the data were used for simulations to test the robustness of the method when omitting dose levels.  Materials and methods  Collection and cultivation of patient-derived tumour specimens  The study has been approved by the Ethics Committee of the Medical Faculty of the University of Tübingen (426/2013BO1). All the patients included in the study were untreated prior to surgical procedure. During collection and cultivation tumour tissues were kept in Dulbecco’s MEM culture medium supplemented with 2% HEPES, 1% Na-pyruvate, 1% non-essential amino acids, 1% penicillin streptomycin (all Biochrom AG, Berlin, Germany) and 10% FBS (PAN Biotech GmbH, Aidenbach, Germany). Fresh tumour material was retrieved from surgical specimens and placed in 50 ml Falcon tubes (Becton Dickinson International, Heidelberg, Germany) containing 15 ml culture medium. Tumour specimens were transported to the laboratory and subsequently cut manually with the use of surgical forceps (BD027R, B. BRAUN, Aesculap, Tuttlingen, Germany) and scalpels (FEATHER Safety Razor Co., Ltd., Osaka, Japan Number 23) into approximately 2–3 mm slices before being placed in petri dishes (3.5 cm diameter) coated with a 1.5% agarose layer (A9539, Sigma–Aldrich, Germany) containing 3 ml culture media. During all incubation times the petri-dishes were kept in 95% humidified atmosphere at 37 _C and 5% CO2. For the purpose of the study tumour material from a total of 25 patient tumours with 10 different tumour histologies was collected (Table 1; n = 3 seminomas, n = 1 chondrosarcoma, n = 3 urinary bladder carcinomas (Ca), n = 3 colorectal Ca (2 colon Ca + 1 rectum), n = 3 breast Ca, n = 1 hepatocellular Ca, n = 3 renal cell Ca, n = 3 prostate Ca, n = 4 glioblastoma multiforme (GBM) and n = 2 cervix Ca). In one GBM patient, the specimen was removed from the analysis because in the 0 Gy sample there was no viable tumour part (based on morphological criteria and BrdU positivity) and no estimation of the background foci could be performed. Histology and selection of malignant cells for analysis were confirmed by an experienced pathologist (M.S.).  Experimental design for evaluation of cH2AX foci in ex vivo irradiated patient-derived tumour specimens  The experimental design has been previously described [45]. Briefly, after initial cultivation for 24 h, the tumour specimens were irradiated typically with 0, 2, 4, 6, 8 Gy single doses (200 kV, RS225 research system Gulmay Medical LTD, Surrey, England; 15 mA; 0.5 mm Cu; dose rate _1 Gy/min). In two tumours, additional doses were delivered to the seminoma sample (#1) doses of 3 and 5 Gy and GBM (#1) 10 
Gy (both previously published [45]). Prior to irradiation, medium containing 20 lmol pimonidazole (hypoxia marker, Natural Pharmacia International, Belmont, MA, USA) and 10 lmol BrdU (proliferation marker, SERVA electrophoresis, Heidelberg, Germany) was added to the specimens for 4 h (20 h post start of cultivation). Immediately after irradiation, the medium was exchanged. BrdU and pimonidazole were added to visualize the microenvironmental parameters at the time of irradiation, i.e. viability, proliferation and oxygenation. The specimens were further incubated for 24 h before they were fixed in 4% formaldehyde and embedded into paraffin.  Tissue staining, imaging and cH2AX foci analysis  The staining procedure has been previously described [43–45]. In brief, three consecutive 3 lm specimen cross-sections from the paraffin-embedded tumour material were stained for (a) haematoxylin and eosin staining (H&E), (b) BrdU (Clone Bu20a, Dako Deutschland GmbH, Hamburg, Germany) and pimonidazole (Natural Pharmacia International, Belmont, MA, USA; immunohistochemistry, IMH) with ARKTM Kit (animal research kit; Dako Deutschland GmbH, Hamburg, Germany) and (c) 40,6-diamidino- 2-phenylindole (DAPI) and cH2AX at Ser139 (Merck Millipore, Upstate, clone JBW301, Darmstadt, Germany; immunofluorescence IMF) with TSATM Kit (T20912, containing goat anti-mouse IgG and tyramide labelled with Alexa 488, Life Technologies GmbH, Molecular probes, Invitrogen, Darmstadt, Germany). For the evaluation of cH2AX foci a Zeiss Axio Imager Z1 Apotome fluorescence microscope controlled by AxioVision 4.8 software (Carl Zeiss, Jena, Germany) was used as previously described [43–45]. Briefly, complete IMH sections were scanned with a digital colour camera (AxioCamMRc, Rev.3 Fire Wire, Carl Zeiss, Jena, Germany, 100_ (EC Plan Neofluar)) and fields for foci analysis were marked in the scan. In the adjacent IMF section the marked fields were identified and 17 individual images/area were taken every 0.25 lm on the Z-axis (z-stack) using a monochrome digital camera (AxioCamMRm, Carl Zeiss, Jena, Germany; motorized scanning stage, Maerzhaeuser, Wetzlar, Germany, 400_, EC Plan Neofluar). The individual images were fused into a single stack image for foci analysis. For each tumour specimen, five to seven IMF-stacks were taken. Evaluation of cH2AX foci was only performed in intact and viable cell nuclei of well oxygenated tumour cells from the outer rim of the tumour specimen. The pimonidazole border from the IMH scanned section was manually transferred in the corresponding IMF section and 50 cells per dose per patientderived tumour sample from the pimonidazole negative (oxic) specimen area were randomly selected for analysis.     Statistical analysis  
The normalized cH2AX foci value was derived as previously reported [45]. In brief, normalization was established to account for aneuploidy, cell cycle effects, partial volume effects and background foci. The normalized foci number (nfoci) per tumour specimen was calculated from,  nfoci=(Area(m)/Area(i))∗Nfoci(i)-cfoci0Gynfoci=Area(m)/Area(i)∗Nfoci(i)-cfoci0Gy 
 where Area(m) is the mean area of all selected nuclei per individual tumour, Area(i) the area of the individual nucleus in which cH2AX foci were evaluated and Nfoci(i) the foci number counted in the corresponding nucleus. For each individual tumour a mean background value of cH2AX cfoci0Gy was determined in sham-irradiated tumour samples. Subsequently the corrected background value of foci was subtracted from the corrected value of each individual cell nucleus counted in the irradiated samples to generate the normalized foci value (nfoci) per nucleus. In case the subtraction was leading to a negative number, the foci value was replaced by zero (0). In order to compare the variability of the residual cH2AX foci numbers across the tumours with different histologies and also within the same tumour histology, an analysis of variance  Table 1.  
Characteristics of residual γH2AX nfoci dose response analysis after ex vivo irradiation. For each patient-derived specimen, the mean nucleus area included in the calculation of normalized γH2AX foci (nfoci) is depicted. The results of the linear regression analysis of residual γH2AX foci dose response are shown for each individual patient and for each different tumour type. The p-value indicates the significance of the linear regression. 
Tumour type Mean nucleus area (SD) (μm2) 
Linear regression analysis 
for each individual tumour 
 
Pooled linear regression 
analysis for each tumour type 
 
Slope (95% 
C.I.)⁎ R squared (r2) Slope⁎ R squared (r2) 
Seminoma Classical 
#1⁎⁎ 90.1 (23.3) 
3.89 (3.55–
4.23) 0.56 3.71 0.60 
Seminoma Classical 
#2 94.2 (27.5) 3.69 (3.34–4.03) 0.64   
Seminoma 
Anaplastic #1⁎⁎ 94.7 (22.2) 2.64 (2.32–2.96) 0.52 2.64 0.52 
Urinary bladder Ca 71.6 (23.0) 1.64 (1.38– 0.39 2.01 0.41 
Tumour type Mean nucleus area (SD) (μm2) 
Linear regression analysis 
for each individual tumour 
 
Pooled linear regression 
analysis for each tumour type 
 
Slope (95% 
C.I.)⁎ R squared (r2) Slope⁎ R squared (r2) 
#1 1.89) 
Urinary bladder Ca 
#2 66.9 (18.3) 
2.72 (2.46–
2.97) 0.64   
Urinary bladder Ca 
#3 67.3 (18.0) 
2.04 (1.75–
2.33) 0.44   
Colorectal Ca #1 54.7 (20.9) 2.02 (1.70–2.33) 0.45 1.94 0.40 
Colorectal Ca #2 53.4 (20.7) 1.92 (1.45–2.39) 0.29   
Colorectal Ca #3 60.1 (24.7) 1.92 (1.71–2.13) 0.40   
Breast Ca #1 54.7 (20.6) 1.61 (1.41–1.79) 0.53 1.68 0.45 
Breast Ca #2 56.1 (13.4) 1.45 (1.24–1.66) 0.43   
Breast Ca #3 62.0 (26.5) 1.99 (1.70–2.24) 0.45   
Hepatocellular Ca #1 64.8 (18.6) 1.86 (1.61–2.11) 0.48 1.56 0.26 
Renal cell carcinoma 
#1 49.3 (10.1) 1.48 (1.27–1.69) 0.44 1.54 0.41 
Renal cell carcinoma 
#2 50.9 (11.8) 
1.80 (1.56–
2.03) 0.47   
Renal cell carcinoma 
#3 39.3 (7.1) 
1.38 (1.19–
1.55) 0.48   
Prostate Ca #1⁎⁎ 50.0 (11.0) 0.83 (0.72– 0.51 1.41 0.61 
Tumour type Mean nucleus area (SD) (μm2) 
Linear regression analysis 
for each individual tumour 
 
Pooled linear regression 
analysis for each tumour type 
 
Slope (95% 
C.I.)⁎ R squared (r2) Slope⁎ R squared (r2) 
0.93) 
Prostate Ca #2⁎⁎ 51.6 (11.0) 2.18 (1.88–2.47) 0.46   
Prostate Ca #3⁎⁎ 53.8 (12.6) 1.19 (1.04–1.32) 0.53   
GBM #1⁎⁎ 54.2 (12.1) 1.24 (0.97–1.51) 0.20 1.07 0.21 
GBM #2⁎⁎ 57.5 (12.0) 0.62 (0.44–0.80) 0.16   
GBM #3 67.2 (21.9) 1.18 (1.00–1.37) 0.38   
Cervix Ca #1 57.4 (15.5) 0.58 (0.42–0.74) 0.21 0.99 0.23 
Cervix Ca #2 58.0 (18.5) 1.18 (0.93–1.44) 0.25   
Chondrosarcoma #1 47.5 (15.9) 0.74 (0.57–0.92) 0.22 0.69 0.17 
⁎ 
p-Value < 0.0001. 
Previously published. 
(ANOVA) test was performed (Sheffe test for multiple comparisons). For the simulation analysis slopes for individual tumours were calculated omitting various dose levels and the ranking of radiation sensitivity was then compared to the ranking based on the slope estimated from the full dose response. Statistical analysis was performed with STATA 11.0 (STATA Corporation, CollegeStation, TX, USA) and graphs were plotted with GraphPad Prism 6 (GraphPad Software, Inc. San Diego, CA, USA). Fit comparison was done with likelihood-ratio tests and p-values <0.05 
were considered statistically significant. Fit comparisons were performed using raw data and mean values along with error bars are reported for visualization purpose.  Results  Characteristics of the patient-derived tumour specimens  All the tumour samples expressed a typical staining pattern for BrdU and pimonidazole, i.e. with the outer rim of the specimen being predominantly pimonidazole-negative and BrdU-positive (data not shown). In total, tumour samples from 25 patients with 10 different tumour types were retrieved and 125 tumour biopsy-specimens were analysed for residual cH2AX foci (Table 1). This includes data from 7 previously published samples [45]. In all the tumours a normal (Gaussian) frequency distribution of the nucleus area per each tumour was observed (data not shown). There was no systematic difference of the nucleus area across the different doses within each individual tumour (data not shown). Therefore a mean value of nucleus area over all doses for each individual tumour was used. The values of nuclear area ranged from 39.3 lm2 (SD: 7.1) for renal cell Ca to 94.2 lm2 (SD: 22.2) for anaplastic seminoma (Table 1). For the calculation of the normalized residual cH2AX foci value a mean ‘‘background” foci value was used from each tumour calculated from the cH2AX foci in the sham-irradiated controls. The background cH2AX foci values ranged from zero for urinary bladder cancer (#3) and colorectal cancer (#1) to 2.58 (SD: 2.69) for GBM (#3)(data not shown). Dose–response of residual cH2AX foci in ex vivo irradiated patientderived tumour samples  Fig. 1 depicts a representative staining pattern of residual cH2AX foci 24 h post 4 Gy irradiation for each tumour type. In all tumour samples a significant linear increase of residual cH2AX foci with increasing radiation dose was observed and the slope of the dose–response as parameter of intrinsic radiation sensitivity was derived (Fig. 2). In Fig. 3 the tumour types are ranked according to their slope values with at one end of the spectrum the sensitive types such as seminomas with large slope values indicating high number of residual foci and on the other hand resistant tumour types such as sarcoma and GBM with small slope values. ANOVA with Sheffe correction of the pooled slope data per tumour type (Table 1) revealed that the variance within a given tumour type is less pronounced than across different types (Sum of Squares (SS) between groups: 19.8, SS within groups: 2.4; p < 0.0001). Simulation analysis of slope estimation and number of dose levels To explore whether the labour-intense manual microscopy visualization and quantification of cH2AX foci with five different dose levels can be simplified without compromising robustness, we used the datasets to perform simulations where dose levels were systematically excluded and the slopes were compared to the slopes estimated from full dose–response relationship considered as reference. Five different scenarios with one to three dose levels were analysed. Based on the slope of full dose response patients were stratified 
into sensitive (>75% percentile), moderate (25–75% percentile) or resistant (<25% percentile; Supplementary Fig. 1). The ranking method is arbitrary and was established empirically due to a lack of standardization. This stratification was used for comparison with the other scenarios (0–4–8 Gy, 0–2–4 Gy, 0–2–6 Gy, 0–6 Gy, 0–8 Gy). The results are summarized in Supplementary Tables 2–6 and Figs. 2–6 and suggest that dose levels might be omitted without major changes in the stratification as long as high doses such as 6 or 8 Gy are included.  Discussion  In the present study we applied our optimized protocol of the cH2AX ex vivo assay to determine intrinsic radiation sensitivity in 25 samples from 10 different tumour types with known differences in tumour radiation sensitivity. The analysis includes previously published data from 7 samples [45]. The slopes of the residual cH2AX foci dose–response curves were different by a factor of more than five across the tumour types (Fig. 3). Importantly, the ranking of the slopes was found to be consistent with the expected radio-responsiveness, i.e. high values in sensitive tumour types such as seminomas and low values in resistant tumour types such as chondrosarcomas and GBM [46–48]. This finding supports the initial hypothesis that the cH2AX ex vivo data correlate with expected radio-responsiveness in a panel of sensitive, moderate and resistant tumours types. The data also support the concept that intrinsic radiation sensitivity of tumour cells contribute to tumour radiation response while there is large overlap between different tumour types. It is important to note that also other radiobiological factors such as tumour hypoxia contribute to tumour radiation response and need to be assessed in order to precisely predict outcome. Our assay is specifically optimized to assess intrinsic radiation sensitivity without being affected by alterations of the microenvironment ex vivo during sampling and cultivation. In the present study, no attempts were made to assess the extentof tumour hypoxia in situ. Conceptually, intrinsic radiation sensitivity is assessed under oxygenated conditions in the outer rim of the ex vivo reoxygenated specimen [45]. Pimonidazole and BrdU were only added to assure that foci are counted solely in viable, proliferating and well oxygenated tumour areas. For future studies it will become important to combine tests of intrinsic radiation sensitivity with hypoxia assessment [49] and gene signatures [50], e.g. by functional imaging or gene expression profiles, and other biomarkers. We have recently started a prospective trial to develop a decision-support-model in head and neck cancer patients including cH2AX ex vivo foci assay, functional imaging, radiomics, genomics and clinico-pathological factors. In the first step, we prospectively collect data for creating predictive models using systems biology approaches and advanced data science. In a second step, we will independently validate the model using biopsies and surgical specimens for future interventional studies, i.e. assigning individual radiation dose with or without prior surgery. To our knowledge we present here first dataset on a panel of tumour types using the cH2AX 
ex vivo foci assay to determine radiation sensitivity. Similarly, freshly excised tumour material for functional tests have been used by others. Tumour samples from breast cancer patients were ex vivo irradiated and the subsequentformation of RAD51 foci was used to detect defects in homologous recombination repair (HRR) of DSBs to identify patients for PARP inhibition [51]. Importantly, in contrast to our method the Rad51 assay is specific for HRR and was not aimed to determine radiation sensitivity across different tumour types. Similar experiments have been performed in patient-derived ovarian cancer xenografts [52]. Differences in intrinsic radiation sensitivity across and among different tumour types have been shown before with the SF2 assay, i.e. the surviving fraction after 2 Gy [12–14]. Overall, it appears that our first data in 10 different tumour types are in line with the SF2 experience. Despite the promising results and the potential for patient stratification [53,54] the SF2 assay was not further developed to be integrated in clinical trials testing individualized radiation oncology. This was among other reasons due to technical and methodological issues resulting in a limited success rate and a long duration of the assay. We believe that the proposed ex vivo cH2AX assay presented here can overcome these limitations by providing rapid results (within few days) at a very high success rate. In addition, the ex vivo cH2AX assay can further be optimized towards higher clinical practicability such as the use of automated microscope counting software [55,56] and the omission of dose levels without compromising robustness (Suppl. Figs. 1–6). The latter analysis is limited by the fact that the ranking system used was arbitrarily and empirically defined as no standardized reference system exists. Further limitations of the present studies include sampling error, sample size and lack of external validation, potential effects of the ex vivo manipulation of the tissues. While the present study demonstrates large differences in intrinsic radiation sensitivity across different tumour types, the next step towards utilizing the assay for personalized radiation oncology would be to apply it in a sufficiently large number of tumours of the same type and correlate the data with established clinic-pathological parameters and patient outcome. Furthermore, the accuracy of the assay will critically depend on the variability of intrinsic radiation sensitivity across an individual tumour, i.e. on the sampling error. Both issues are addressed in an ongoing study in a cohort of prostate cancer patients. In conclusion, we confirm the clinical feasibility of the cH2AX ex vivo assay. The slopes of the residual foci number per dose unit are well in line with the expected differences in radioresponsiveness of different tumour types implying that intrinsic radiation sensitivity contributes to tumour radiation response. Thus, this assay has a promising potential for individualized radiation oncology and prospective validation is warranted.  Financial support  This study was supported by the Applied Clinical Research (AKF-Angewandte Klinische Forschung) program (Medical Faculty Tuebingen, project number E.03.35204.2) and by the German Consortium for Translational Cancer Research (DKTK) partner site Tübingen. 
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  Fig. 1. Typical staining pattern of residual cH2AX foci: representative immunofluorescent images of residual cH2AX foci 24 h after 4 Gy ex vivo irradiation of patient-derived specimens are shown for each different tumour type included in the study. Original image magnification 400_. DNA DSB marker cH2AX foci in green (Alexa 488) and DNA counterstain in blue to visualize the cell nuclei (DAPI). Heterogeneity in the cell nuclear area can be observed (Table 1). The patient tumour sample used for the generation of the image, numbered according to Table 1 is also noted. The large cH2AX positive areas in some of the samples, e.g. seminoma, were not evaluated in the foci analysis and may represent either tumour cells in S phase, inflammatory cells or cells undergoing necrosis or apoptosis.       
     
 Fig. 2. Dose–response of residual cH2AX foci in ex vivo irradiated patient-derived tumour samples: linear regression analysis of residual cH2AX nfoci dose response across the different tumour types for each individual patient evaluated (Table 1). Patient-derived tumour specimen from different tumour types with known differences in clinical radiation sensitivity irradiated ex vivo with graded single doses after 24 h cultivation prior to irradiation. Symbols represent mean values of residual cH2AX nfoci quantified inat least 50 cells per dose level and error bars 95% confidence intervals. The parameters of the linear regression analysis (slope value, r-squared, p-value) for each patientderived specimen are noted. For cervix cancer #2 the sample irradiated with 6 Gy did not contain evaluable cells and was therefore omitted from the analysis.     
 Fig. 3. The slope of the dose–response of the cH2AX nfoci in relation to the different tumour types with known differences in clinical radiation response. The slope value of each individual patient (Fig. 2) and 95% confidence intervals of the slope estimation are shown. The slope values, as marker of intrinsic radiation sensitivity of tumour cells, are well in line with the expected tumour-type specific differences of radio-responsiveness observed in the clinic after fractionatedradiation therapy.     
